XML 39 R29.htm IDEA: XBRL DOCUMENT v3.24.3

Basis of presentation (Tables)

9 Months Ended

Sep. 30, 2024

Accounting Policies [Abstract]

Schedule Of Impact Of Restatement On Certain Line Items And Balance Sheet

The tables below present the impact of the revision on the line items within the Company’s consolidated financial statements for the relevant periods:

		Three months ended												Nine months ended
		September 30, 2023												September 30, 2023
		U.S $ in millions (except per share amounts)
		(Unaudited)
		As previously reported				Adjustment				As revised				As previously reported				Adjustment				As revised
Other asset impairments, restructuring and other items		$	46				11				57			$	241				34				276
Operating income (loss)			355				(11	)			344				(289	)			(34	)			(323	)
Income (loss) before income taxes			75				(11	)			64				(1,097	)			(34	)			(1,131	)
Income taxes (benefit)			(12	)			§				(12	)			(48	)			§				(48	)
Net income (loss)			88				(11	)			77				(1,048	)			(34	)			(1,082	)
Net income (loss) attributable to Teva			80				(11	)			69				(988	)			(34	)			(1,022	)
Earnings (loss) per share attributable to ordinary shareholders:
Basic and diluted loss per share		$	0.07				(0.01	)			0.06			$	(0.88	)			(0.04	)			(0.91	)

§ Represents an amount less than $0.5 million.

		September 30, 2023
		As previously reported				Adjustment				As revised
		(Unaudited)
Deferred income taxes		$	1,748				7				1,755
Total assets			42,088				7				42,095
Other taxes and long-term liabilities			3,818				132				3,950
Total long-term liabilities			23,182				132				23,314
Total liabilities			34,576				132				34,708
Teva shareholders’ equity:
Accumulated deficit			(13,870	)			(125	)			(13,995	)
Total equity			7,512				(125	)			7,387
Total liabilities and equity		$	42,088				7				42,095

X

- References

No definition available.

+ Details

Name:	us-gaap_AccountingPoliciesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

+ Details

Name:	us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration